▷ Viromed Group takes over terraplasma medical GmbH

10.12.2021 – 16:23

terraplasma medical GmbH

Garching b. Munich (ots)

The majority takeover of terraplasma medical GmbH by Viromed Plasma GmbH, a company of the Viromed Group, was announced today. Terraplasma GmbH will continue to be involved as a partner in terraplasma medical GmbH in order to continue to contribute its expertise in the field of cold atmospheric plasmas in the future.

The aim of Viromed and terraplasma is to jointly build the world’s leading company and innovation leader for medical products with cold atmospheric plasma in a wide variety of medical fields of application.

Cold atmospheric plasma inactivates bacteria, multi-resistant pathogens, viruses and also fungi in a highly effective physical-chemical way. Its use in medical technology can revolutionize, supplement and, in some cases, replace conventional treatment methods, for example in surgery for postoperative wounds to avoid infections. In nursing, cold atmospheric plasma offers a therapy option for chronic, often long-term and non-healing wounds. Cold plasma treatment reduces the use of antibiotics or cortisone and does not cause allergic side effects or pain. The plasma care® product line developed by terraplasma medical GmbH for this purpose, which uses cold atmospheric plasma in medical technology, is to be expanded further in the future.

Clinical experience over the last few years has shown that this new form of therapy, in addition to its bactericidal and healing properties, offers additional benefits for the health system: e.g. a reduction in care and dressing costs or the avoidance of complications and longer hospital stays during postoperative use. By reducing the use of antibiotics, the resulting resistances can be avoided and less anti-inflammatory drugs can be used in dermatology. Ultimately, successful therapy for diabetic feet or open legs, for example, significantly improves the quality of life of the patient.

With the entry of Viromed, the already existing, very successful cooperation is to be significantly intensified and expanded. This applies in particular to the broad marketing of the plasma care® product range, says Uwe Perbandt. The Perbandt family is the owner of the Viromed Group through its holding company, Perbamed Invest GmbH.

Jens Kirsch, CEO of terraplasma medical GmbH, is pleased to have won an extremely strong sales and financially strong partner in the Viromed Group. Dr. Julia Zimmermann, CEO of terraplasma GmbH, a spin-off of the Max Planck Society, is enthusiastic about developing innovative medical products for various medical applications together with terraplasma medical GmbH and establishing them successfully on the market.

The departing shareholders of the investor group around Kuenheim Familiaris GmbH are proud to have accompanied such a successful company development, said Fabian von Kuenheim.

the terraplasma medical GmbH based in Garching near Munich was founded in 2016 by terraplasma GmbH, a spin-off from the Max Planck Society. The idea: Use of the antimicrobial and tissue-regenerating effect of cold plasma in medicine and care with a small, handy device for stationary and mobile use. In 2019 the plasma care® was approved for the treatment of chronic wounds, in 2021 the plasma derma care® for the treatment of skin diseases induced by bacteria and fungi. The plasma intensive care, a device for reducing the bacterial load in the oropharynx in ventilated intensive care patients, is currently in the approval process.

the Viromed Group based in Pinneberg near Hamburg has been producing disinfection devices with the aid of plasmas and ionization for professional use in hospitals and practices for more than 15 years and is recommended as the only manufacturer by the German Association of Pneumologists and Respiratory Medicine. As early as 2005, Viromed commissioned SARS virus tests in safety laboratories and has since developed into the German market leader in pandemic control with products for hygienic protective measures, including masks, disinfection devices for diagnostics, including rapid antigen tests, point-of-care antibody determination and real-time testing. PCR test (rRT-PCR) and for digital networking. Viromed has a sales network with over 1,100 hospitals, over 2,000 old people’s homes as well as 7,000 pharmacies and 12,000 medical practices. The Viromed Group is also the main supplier of antigen tests and room fans in many federal states, federal ministries and many large DAX companies.

Press contact:

terraplasma medical GmbH
Jens Kirsch (CEO)
Parkring 32
85748 Garching b. Munich
Tel: +49 (0)89 58805530
[email protected]
Viromed Group
Uwe Perbandt (representative of the owner family)
Flensburger Str. 18
25421 Pinneberg
Tel: +49 (0)40 429347077
[email protected]

Original content from: terraplasma medical GmbH, transmitted by news aktuell


Leave a Reply

Your email address will not be published.